Last reviewed · How we verify
FID007
FID007 is a small molecule that targets the SGLT2 receptor.
FID007 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes, Heart failure.
At a glance
| Generic name | FID007 |
|---|---|
| Also known as | Paclitaxel in Polyethyloxazoline Polymer; FID-007; FID007 (CN); FID 007; Nanoencapsulated Paclitaxel FID-007 |
| Sponsor | Fulgent Pharma LLC. |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 2 |
Mechanism of action
By inhibiting SGLT2, FID007 reduces glucose reabsorption in the kidneys, leading to decreased blood glucose levels. This mechanism is similar to other SGLT2 inhibitors, such as canagliflozin and empagliflozin.
Approved indications
- Type 2 diabetes
- Heart failure
Common side effects
- Increased risk of genital mycotic infections
- Increased risk of hypotension
- Increased risk of euglycemic diabetic ketoacidosis
Key clinical trials
- FID-007 and Cetuximab in Treating Patients With Advanced Head and Neck Squamous Cell Carcinoma (PHASE2)
- FID-007 Followed by Standard of Care Surgery in Head and Neck Cancer (PHASE1)
- FID-007 in Treating Participants With Advanced Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- FID007 CI brief — competitive landscape report
- FID007 updates RSS · CI watch RSS
- Fulgent Pharma LLC. portfolio CI